The abstract is read at the publisher; the summary is JClub's.
In 111 patients with chronic coronary artery disease, daily colchicine 0.6 mg for 24 weeks did not reduce ascending aorta FDG uptake versus placebo (p=0.38).
- Why it matters: The cardiovascular benefits of colchicine in coronary artery disease are not well explained, and the study tests whether it lowers vascular inflammation and blood pressure through measurable pathways.
- What they did: A randomized, double-blind, placebo-controlled trial used 18F-fluorodeoxyglucose PET to quantify mean maximum target-to-background ratio over 24 weeks, with systemic inflammatory markers and blood pressure as secondary outcomes. A complementary 4-week study in spontaneously hypertensive rats assessed vascular inflammation and remodeling using immunohistochemistry, myography, and proteomics.
- The result: Colchicine was linked to a reduction in neutrophil-to-lymphocyte ratio (p=0.033), a trend toward lower high-sensitivity C-reactive protein (p=0.060), and attenuated systolic/diastolic blood pressure increases (p=0.046 and p=0.048); in SHRs it attenuated hypertension progression and reduced inflammation and extracellular matrix remodeling in mesenteric resistance arteries.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.